Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Budesonide orodispersible tablets - Dr Falk Pharma

Next Previous
Drug Profile

Budesonide orodispersible tablets - Dr Falk Pharma

Alternative Names: BUET; Jorveza

Latest Information Update: 19 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dr Falk Pharma
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eosinophilic oesophagitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Eosinophilic oesophagitis
  • Phase III Graft-versus-host disease
  • Phase II Gastrointestinal disorders

Most Recent Events

  • 07 Oct 2021 Dr Falk Pharma completes a phase III trial for Eosinophilic oesophagitis in Belgium, UK, Germany, Netherlands, Denmark, Spain, Italy (PO) in December 2020 (EudraCT2014-001485-99) (NCT02493335)
  • 26 Apr 2021 Phase-III clinical trials in Eosinophilic oesophagitis in Germany (PO) (EudraCT2020-001314-37)
  • 14 Jan 2021 Dr Falk Pharma initiates a phase III trial for Eosinophilic oesophagitis in Germany (PO) (EudraCT2017-003516-39)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top